General Anesthesia Ups Heart Failure Risk After Valve Surgery

METHODOLOGY

  • Researchers conducted a retrospective observational cohort study using data from the TriNetX Global Collaborative Network, including adults who underwent their first TAVR from 2015 to 2024.
  • Patients either received general or nongeneral anesthesia, the latter of which was comprised of moderate sedation or nerve block, regional, epidural, local, or injection anesthesia.
  • A target trial emulation framework was used to compare the two types of anesthesia, and 1:1 propensity score matching was used to balance baseline characteristics.
  • A total of 1793 patients were included in each anesthesia group (mean age, 78.7 years; 44.6% women; more than 90% White individuals).
  • Clinical outcomes assessed at 30, 90, and 365 days included all-cause mortality, acute kidney injury, major vascular complications, respiratory failure, and hospital readmission.

TAKEAWAY

  • At 1 year, the incidence of heart failure was higher in the general anesthesia group than in those who received nongeneral anesthesia (HR, 1.44; P = .023).
  • At 1 month after TAVR, all-cause mortality did not differ between patient groups (hazard ratio [HR], 1.19; P = .300), and no differences were observed in rates of stroke, kidney injury, myocardial infarction, atrial fibrillation, major vascular complications, heart failure, or respiratory failure.
  • At 90 and 365 days, all-cause mortality and most major complications did not differ between groups.

 

 

https://www.medscape.com/viewarticle/general-anesthesia-ups-heart-failure-risk-after-valve-2026a1000pcv